Comprehensive assessment of Parkinson's Disease (PD) requires validated rating scales that capture motor symptoms, non-motor features, functional disability, and quality of life. This page documents the key assessment instruments used in PD clinical care and research.
The Hoehn and Yahr scale is the most widely used clinical rating scale for Parkinsonism, originally published in 1967 and modified subsequently. It provides a global measure of disease severity based on clinical staging.
| Stage | Description |
|---|---|
| 0 | No signs of disease |
| 1 | Unilateral disease |
| 1.5 | Unilateral and axial involvement |
| 2 | Bilateral disease, without impairment of balance |
| 2.5 | Mild bilateral disease, with recovery on pull test |
| 3 | Mild to moderate bilateral disease; some postural instability; physically independent |
| 4 | Severe disability; still able to walk or stand unassisted |
| 5 | Wheelchair bound or bedridden unless aided |
Clinical Utility: The Hoehn and Yahr scale is simple to administer and correlates with dopaminergic neuron loss as measured by SPECT imaging. It remains a standard outcome measure in clinical trials despite its categorical nature.
The Movement Disorder Society revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is the gold standard for comprehensive PD assessment. Released in 2008, it addresses limitations of the original 1987 UPDRS.
Structure:
Total Score Range: 0-260 (higher = more severe)
Key Improvements over Original UPDRS:
The Schwab and England scale provides a quick global measure of functional independence:
The MoCA is a brief 30-point cognitive screening test sensitive to mild cognitive impairment in PD:
Cutoff: <26 suggests cognitive impairment
Specifically designed for PD, the PD-CRS assesses:
Comprehensive assessment of multiple cognitive domains, sensitive to executive dysfunction in PD.
The PDSS assesses nocturnal and sleep-related symptoms:
Measures daytime sleepiness, important given the high prevalence of sleep disorders in PD.
Gold standard for depression screening in PD.
Anxiety is common in PD and impacts quality of life.
Olfactory dysfunction is one of the earliest and most prevalent non-motor symptoms in PD:
Combined score (TDI): Normal >30.1, hyposmia 16-30.1, anosmia <16
See: Olfactory testing in PD diagnostics
Useful for identifying REM sleep behavior disorder, a prodromal marker.
Measures functional mobility:
PD cutoff: >13.5 seconds suggests fall risk
Measures gait velocity, a predictor of disease progression and falls.
Specifically assesses freezing of gait, a disabling motor phenomenon in advanced PD.
Evaluates postural stability and balance impairment.
The most widely used PD-specific quality of life measure:
Generic quality of life measure for comparison across conditions.
These clinical scales correlate with objective biomarkers:
Common primary and secondary endpoints in PD clinical trials:
| Endpoint | Scale | Clinical Meaningfulness |
|---|---|---|
| Primary | MDS-UPDRS total | Comprehensive disease impact |
| Primary | ON/OFF time | Motor fluctuation control |
| Secondary | MoCA | Cognitive progression |
| Secondary | PDQ-39 | Quality of life |
| Exploratory | FOG-Q | Freezing assessment |